Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternative Treatment Study for Long COVID
NCT06441955Phase 4Recruiting
- Sponsor
- Well-Konnect Healthcare Services and Research Firm
- Start
- Mar 2024
- Primary completion
- Sep 2030
- Modality
- Vaccines & Immunotherapeutics, Orthosteric Ligands, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Nirmatrelvir, elasomeran in post acute COVID-19 syndrome, sponsored by Well-Konnect Healthcare Services and Research Firm. Started Mar 2024; status: recruiting.
02
Drugs
Nirmatrelvirelasomeran
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT06441955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441955.